0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Innovation Lab Capabilities

In our efforts to provide the right blend of innovation and value to our clients, ACROBiosystems has NEW Lab Services! Our scientists have implemented and mastered numerous assay platforms over the years. Our recent introduction of the INNOVATION LAB offers TCR Screening Technology and the MSD SQ120 into our assay development portfolio.

  • MSD – ECL Multiplexing Services
  • TCR Screening Service
  • qPCR Services
  • Assay Services

MSD-ECL Platform: Broad Range Multiplex Detection via Electrochemiluminescence

ACROBiosystems offers an array of MSD-based immunoassays with a proven increase in both dynamic range and sensitivity, made possible through electro chemiluminescent labeling. ACROBiosystems utilizes our expertise to accurately access clients’ needs and to guide in the design of assays more sensitive than traditional ELISA.

Still have questions?

  1. ACROBiosystems’s experts are here to help.
  2. Call us at: +1 302-644-5472 or email at: services@acrobiosystems.com.
i. How the Meso Scale Discovery Platform (MSD-ECL) Works?

Using electrochemiluminescently-labeled detection antibodies, the MSD-ECL platform detects excitation near electrodes located in the bottom of each microplate. As electricity is applied to the plate electrodes, the electrochemiluminescent labels are stimulated to emit light. The intensity of those emissions is then converted to a quantitative measurement of the target analytes in cell supernatant, serum, plasma or whole blood.

msd_ecl
ii. Ideal MSD Applications: For Multiplexing and Complex Matrices

The MSD-ECL platform offers great flexibility with stable, non-radioactive, and easily conjugated labels. Because of these factors, this technology can be applied to all types of traditional ELISAs, such as direct, indirect, sandwich or competitive assays at an increased sensitivity level that can detect samples with concentrations as low as 0.1pg/mL.

We have also found MSD assays are optimal for complex matrices as they typically yield low interference from components like serum or plasma. MSD is particularly advantageous in that its bridging formats are not specific for species or antibody subclass.

Examples of samples:
  1. Tissue culture: quantification of protein in tissue culture supernatant.
  2. Serum/plasma: Serum/plasma kits provide assay-specific components for the quantitative determination of biomarkers in serum and plasma samples.
  3. Whole cell lysate: detection of biomarkers in whole cell lysates.
  4. Other: common high-throughput screening and assay development.

Meso Scale Discovery (MSD-ECL) can be applied in our work with biomarker screening, immunogenicity, pharmacokinetics (PK) and cell-based assays.

  • Biomarker
  • Immunogenicity
  • Pharmaceutical
  • Cell-based assays
iii. Key MSD-ECL Benefits: High Sensitivity and Broad Dynamic Range
Top Benefits of MSD Assays:
  • High Sensitivity
  • Small Sample Volumes
  • Multiplexing
  • Broad Dynamic Range
  • Low Background
  • High Throughput

MSD’s proprietary multi-array technology can provide significantly increased sensitivity and dynamic range over standard ELISA with the added benefit of multiplexing. Fast, yet continuous, non-destructive reads produce consistent assay data with low sample volume requirements and minimal reagent consumption. An added benefit of the electrochemiluminescence (ECL) detection technology is that it reduces assay background by separating the excitation mechanism from the signal.

With a broad range of quantitation, assays conducted using MSD technology are cost-effective and exhibit a reduced need for repeats stemming from readings above the ULOQ or below the LLOQ. This means more valid data points from sample sets in a single run than with other similar platforms.

The combination of rapid read times and the ability to perform multiple, simultaneous tests on a single sample increases productivity, conserves sample, and delivers results quickly.

iv. ACROBiosystems’s MSD-ECL Platform Expertise

ACROBiosystems’s scientists have particular expertise using MSD-ECL for complex matrices and have had proven success meeting the demands of even the most challenging bioanalytical assays. Let us show you how increased sensitivity and reduced sample requirements can open new possibilities in your studies today.

Assay for full length reads of V(D)J regions

With our high-throughput sequencing and T-cell receptor repertoire analysis technology, our TCR screening service can help you dynamically visualize repertoire diversity and testng across different sequencing samples.

TCR Screening Workflow
  • Pre and post treatment sample collecton
  • Library generaton
  • Repertoire analysis
  • High-throughput sequencing

Quantitative Real-time PCR (q-PCR) Platform: RNA/DNA assays

Based on our Quantitative Real-time PCR (q-PCR) platform, ACROBiosystems offers RNA/DNA analysis options to help expedite your research. We offer a full range of sample analysis options from isolation and quantitation up to sequencing. Our quantitative PCR platform produces highly specific and reproducible results. We specialize in T cell analysis and offer other customized analysis options for client needs.

DNA and RNA assays services:
  • TaqMan® Assay & SYBR® Green Dye-Based Platforms
  • RNA/DNA extraction services
  • cDNA synthesis for RNA profiling and gene expression analysis
  • RNA/DNA quantitation and quality assessment
  • Quantification of Gene Expression
  • Detection of single/double copy homologs
  • Assay Development
  • ELISA
  • ADA
  • Cell Based
  • NAB
SPEAK TO A SCIENTIST
Please complete this questionnaire to receive additional information related to your service and/or product needs. An ACROBiosystems scientist will respond to your request within 24 hours of submission.
For additional information about ACROBiosystems Innovation Lab’s platforms or services, please call us at: +1 302-644-5472 or email at: services@acrobiosystems.com.

This web search service is supported by Google Inc.

totop